Post
CNBC
cnbc.com
did:plc:m7ks2xhfuku7errrtfjux2lg
The cost of GLP-1 drugs is falling, and pill versions are hitting the U.S. market. For restaurant chains and snacking giants, higher adoption of weight loss and diabetes treatments poses a threat to their sales — or an opportunity.
Full story: cnb.cx/4v8VWAv
2026-03-25T21:00:21.368Z